ArticleDiscover oncology2025
Predictive value of DWI signal and IVIM of pelvic bone marrow for hematological toxicity in rectal cancer patients undergoing concurrent chemoradiotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate DWI signal and IVIM for assessing hematological toxicity (HT) in patients undergoing chemoradiotherapy for rectal cancer.
methodsThis study retrospectively collected IVIM data from rectal cancer patients before and after concurrent chemoradiotherapy. The hematological grading of toxicity followed to the standardized criteria established by the WHO. Grading 2 and above is classified as HT2+, while grading below 2 is classified as HT2-. Pelvic bone marrow DWI signals were categorized into high and iso-low signal, and the signal intensity ratios (SIR) between marrow and muscle were calculated. Analyses were conducted to compare the clinical data, DWI signal, and IVIM parameters of pelvic bone marrow between the HT2 + and HT2- groups. Then, modelling was performed based on these meaningful factors.
results42 cases were enrolled in this study, 21 in each of the HT2- and HT2 + groups. There were no statistically significant differences in the clinical data between HT2 + and HT2- groups (all P > 0.05). Differences were observed in pre-treatment DWI signal, pre-treatment SIR marrow−muscle, and pre-treatment f value between the two groups (all P < 0.05). The AUC of the pre-treatment SIR marrow−muscle, f value, and their combination were 0.717, 0.737 and 0.816 respectively for predicting HT2+. However, no statistically significant differences were found among these AUCs (all P > 0.05).
conclusionPre-treatment high DWI signals and lower f-values in pelvic bone may be associated with HT2 + following chemoradiotherapy for rectal cancer. These preliminary findings suggest that DWI parameters may offer valuable insights for predicting hematological toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.